Lymphocytes and ischemia-reperfusion injury.
Ischemia reperfusion injury (IRI) is a common and important clinical problem in many different organ systems, including kidney, brain, heart, liver, lung, and intestine. IRI occurs during all deceased donor organ transplants. IRI is a highly complex cascade of events that includes interactions between vascular endothelium, interstitial compartments, circulating cells, and numerous biochemical entities. It is well established that the innate immune system, such as complement, neutrophils, cytokines, chemokines, and macrophages participate in IRI. Recent data demonstrates an important role for lymphocytes, particularly T cells but also B cells in IRI. Lymphocytes not only participate in augmenting injury responses after IRI, but could also be playing a protective role depending on the cell type and stage of injury. Furthermore, lymphocytes appear to be participating in the healing response from IRI. These new data open the possibility for lymphocyte targeted therapeutics to improve the short and long term outcomes from IRI.
Linfert
Douglas
D
Nephrology Division, Johns Hopkins University, Baltimore, MD 21205, USA.
Chowdhry
Tayseer
T
Rabb
Hamid
H
D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002102:Cadaver; D004285:Dogs; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D051379:Mice; D016513:Mice, SCID / Q000276:immunology; D023421:Models, Animal; D016377:Organ Transplantation / Q000009:adverse effects*; D015427:Reperfusion Injury / Q000276:immunology* / Q000503:physiopathology / Q000517:prevention & control; D012189:Retrospective Studies; D013601:T-Lymphocytes / Q000276:immunology*; D014019:Tissue Donors
D007166:Immunosuppressive Agents